Literature DB >> 19187445

Alterations of myelin-specific proteins and sphingolipids characterize the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-Pick disease type A.

Barbara Buccinnà1, Marco Piccinini, Alessandro Prinetti, Federica Scandroglio, Simona Prioni, Manuela Valsecchi, Barbara Votta, Silvia Grifoni, Elisa Lupino, Cristina Ramondetti, Edward H Schuchman, Maria Teresa Giordana, Sandro Sonnino, Maria Teresa Rinaudo.   

Abstract

Niemann-Pick disease (NPD) type A is a neurodegenerative disorder caused by sphingomyelin (SM) accumulation in lysosomes relying on reduced or absent acid sphingomyelinase (ASM) activity. NPD-A patients develop progressive neurodegeneration including cerebral and cerebellar atrophy, relevant Purkinje cell and myelin deficiency with death within 3 years. ASM'knock-out' (ASMKO) mice, an animal model of NPD-A, develop a phenotype largely mimicking that of NPD-A. The mechanisms underlying myelin formation are poorly documented in ASMKO mice. In this study we determined the content of four myelin-specific proteins, myelin basic protein (MBP), 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), myelin associated glycoprotein (MAG) and proteolipid protein (PLP), and that of myelin-enriched sphingolipids in the brains of ASMKO and wild-type mice in early stages of post-natal (pn) life. Protein and mRNA analysis revealed that in ASMKO mice beginning from 4 post-natal weeks (wk-pn), the expression levels of MAG, CNP, and MBP were below those observed in wild-type mice and the same applied to PLP at 10 wk-pn. Moreover, at 4 wk-pn the expression of SOX10, one of the transcription factors involved in oligodendrocyte development and maintenance was lower in ASMKO mice. Lipid analysis showed that SM and the gangliosides GM3 and GM2 accumulated in the brains of ASMKO mice, as opposed to galactocerebroside and galactosulfocerebroside that, in parallel with the mRNAs of UDP-galactose ceramide galactosyltransferase and galactose-3-O-sulfotransferase 1, the two transferases involved in their synthesis, decreased. Myelin lipid analysis showed a progressive sphingomyelin accumulation in ASMKO mice; noteworthy, of the two sphingomyelin species known to be resolved by TLC, only that with the lower Rf accumulated. The immunohistochemical analysis showed that the reduced expression of myelin specific proteins in ASMKO mice at 10 wk-pn was not restricted to the Purkinje layer of the cerebellar cortex but involved the cerebral cortex as well. In conclusion, reduced oligodendrocyte metabolic activity is likely to be the chief cause of myelin deficiency in ASMKO mice, thus shedding light on the molecular dysfunctions underlying neurodegeneration in NPD-A.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19187445     DOI: 10.1111/j.1471-4159.2009.05947.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

Review 1.  Secondary alterations of sphingolipid metabolism in lysosomal storage diseases.

Authors:  Alessandro Prinetti; Simona Prioni; Elena Chiricozzi; Edward H Schuchman; Vanna Chigorno; Sandro Sonnino
Journal:  Neurochem Res       Date:  2011-01-05       Impact factor: 3.996

2.  Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.

Authors:  Glyn Dawson; Jingdong Qin
Journal:  Biochem Biophys Res Commun       Date:  2010-12-03       Impact factor: 3.575

Review 3.  Types A and B Niemann-Pick disease.

Authors:  Edward H Schuchman; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2016-12-16       Impact factor: 4.797

Review 4.  Brain pathology in Niemann Pick disease type A: insights from the acid sphingomyelinase knockout mice.

Authors:  Maria Dolores Ledesma; Alessandro Prinetti; Sandro Sonnino; Edward H Schuchman
Journal:  J Neurochem       Date:  2011-01-07       Impact factor: 5.372

5.  Emerging links between pediatric lysosomal storage diseases and adult parkinsonism.

Authors:  Daniel Ysselstein; Joshua M Shulman; Dimitri Krainc
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

Review 6.  Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders.

Authors:  Marco Piccinini; Federica Scandroglio; Simona Prioni; Barbara Buccinnà; Nicoletta Loberto; Massimo Aureli; Vanna Chigorno; Elisa Lupino; Giovanni DeMarco; Annarosa Lomartire; Maria Teresa Rinaudo; Sandro Sonnino; Alessandro Prinetti
Journal:  Mol Neurobiol       Date:  2010-02-03       Impact factor: 5.590

7.  Glycosphingolipids.

Authors:  Elena Chiricozzi; Massimo Aureli; Laura Mauri; Erika Di Biase; Giulia Lunghi; Maria Fazzari; Manuela Valsecchi; Emma Veronica Carsana; Nicoletta Loberto; Alessandro Prinetti; Sandro Sonnino
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

Review 8.  Lipid rafts in neurodegeneration and neuroprotection.

Authors:  Sandro Sonnino; Massimo Aureli; Sara Grassi; Laura Mauri; Simona Prioni; Alessandro Prinetti
Journal:  Mol Neurobiol       Date:  2013-12-22       Impact factor: 5.590

9.  Reversibility of neuropathology in Tay-Sachs-related diseases.

Authors:  María-Begoña Cachón-González; Susan Z Wang; Robin Ziegler; Seng H Cheng; Timothy M Cox
Journal:  Hum Mol Genet       Date:  2013-09-20       Impact factor: 6.150

Review 10.  A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis.

Authors:  Brianna M Quinville; Natalie M Deschenes; Alex E Ryckman; Jagdeep S Walia
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.